tumor antigen loaded autologous dendritic cells

This is an investigational autologous dendritic cell vaccine developed by Inge Marie Svane and colleagues at Herlev Hospital for the treatment of metastatic renal cell carcinoma. The therapy involves harvesting a patient's own dendritic cells, maturing them ex vivo, and loading them with tumor-specific antigens. Depending on the patient's HLA-A2 status, the cells are pulsed with either a cocktail of synthetic peptides (specifically survivin and telomerase) or autologous/allogeneic tumor lysate. These antigen-loaded dendritic cells are then administered intradermally to stimulate a systemic T-cell mediated immune response against the tumor. In clinical studies, this vaccine has been evaluated in combination with low-dose interleukin-2 and thymosin alpha 1 to enhance the expansion and anti-tumor activity of the induced T cells.

Other names

autologous dendritic cell vaccinesurvivin and telomerase peptide-pulsed dendritic cellstumor lysate-pulsed dendritic cellsDC vaccination